Human Genetics

, Volume 119, Issue 3, pp 241–254

Does the mitochondrial genome play a role in the etiology of Alzheimer’s disease?

  • Joanna L. Elson
  • Corinna Herrnstadt
  • Gwen Preston
  • Leon Thal
  • Christopher M. Morris
  • J. A. Edwardson
  • M. Flint Beal
  • Douglass M. Turnbull
  • Neil Howell
Original Investigation

DOI: 10.1007/s00439-005-0123-8

Cite this article as:
Elson, J.L., Herrnstadt, C., Preston, G. et al. Hum Genet (2006) 119: 241. doi:10.1007/s00439-005-0123-8

Abstract

We report here the analyses of complete mtDNA coding region sequences from more than 270 Alzheimer’s disease (AD) patients and normal controls to determine if inherited mtDNA mutations contribute to the etiology of AD. The AD patients and normal individuals were carefully screened and drawn from two populations of European descent in an effort to avoid spurious effects due to local population anomalies. Overall, there were no significant haplogroup associations in the combined AD and normal control sequence sets. Reduced median network analysis revealed that the AD mtDNA sequences contained a higher number of substitutions in tRNA genes, and that there was an elevated frequency of replacement substitutions in the complex I genes of the control sequences. Analysis of the replacement substitutions indicated that those arising in the AD mtDNAs were no more deleterious, on average, than those in the control mtDNAs. The only evidence for the synergistic action of mutations was the presence of both a rare non-conservative replacement substitution and a tRNA mutation in 2 AD mtDNAs, from a total of 145, whereas such a combination of mutations was not observed in the control sequences. Overall, the results reported here indicate that pathogenic inherited mtDNA mutations do not constitute a major etiological factor in sporadic AD. At most, a small proportion of AD patients carry a pathogenic mtDNA mutation and a small proportion of cognitively normal aged individuals carry a mtDNA mutation that reduces the risk of AD.

Supplementary material

439_2005_123_MOESM1_ESM.doc (104 kb)
Electronic supplementary material 1
439_2005_123_MOESM2_ESM.doc (600 kb)
Electronic supplementary material 2
439_2005_123_MOESM3_ESM.doc (200 kb)
Electronic supplementary material 3

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Joanna L. Elson
    • 1
  • Corinna Herrnstadt
    • 2
  • Gwen Preston
    • 2
  • Leon Thal
    • 3
  • Christopher M. Morris
    • 4
  • J. A. Edwardson
    • 4
  • M. Flint Beal
    • 5
  • Douglass M. Turnbull
    • 1
    • 6
  • Neil Howell
    • 7
    • 8
  1. 1.Mitochondrial Research Group, School of Neurology, Neurobiology, and PsychiatryThe University of Newcastle upon TyneNewcastle upon TyneUnited Kingdom
  2. 2.MitoKor Inc. (now MIGENIX Corp.)San DiegoUSA
  3. 3.Department of NeurosciencesUniversity of California San DiegoSan DiegoUSA
  4. 4.Institute for the Health of the Elderly, Newcastle General HospitalNewcastle upon TyneUnited Kingdom
  5. 5.Department of NeurologyCornell University Medical CollegeNew YorkUSA
  6. 6.MRC/University of Newcastle upon Tyne Development Centre for Clinical Brain AgeingNewcastle upon TyneUnited Kingdom
  7. 7.MIGENIX Corp.San DiegoUSA
  8. 8.Department of Radiation OncologyThe University of Texas Medical BranchGalvestonUSA